IFIH1 (MDA5) is a cytoplasmic innate immune receptor that functions as a sentinel for viral and aberrant nucleic acids, triggering antiviral defense responses 1. The protein detects diverse viral pathogens including picornaviruses, coronaviruses (SARS-CoV-2), dengue virus, and reovirus through recognition of long double-stranded RNA (>1 kb) and unmethylated mRNA 23. Upon ligand binding, IFIH1 associates with MAVS to activate TBK1 and IKBKE kinases, which phosphorylate IRF3 and IRF7 transcription factors, culminating in type I interferon and pro-inflammatory cytokine production 4. Beyond antiviral immunity, IFIH1 recognizes endogenous dsRNAs; notably, the novel transcript IBR1 activates IFIH1 in acute respiratory distress syndrome by binding its helicase domain, driving inflammatory M1 macrophage polarization 5. Clinically, IFIH1 dysfunction associates with immunodeficiency and impaired antiviral responses, while gain-of-function variants contribute to autoimmune disease. The rs1990760 polymorphism confers type 1 diabetes susceptibility, particularly in Caucasian populations 6. IFIH1-targeted autoimmunity manifests as dermatomyositis with anti-MDA5 antibodies, characterized by rapidly progressive interstitial lung disease and vasculopathy 7. Additionally, IFIH1 activation through endogenous dsRNA signaling represents a therapeutic mechanism for DNA-demethylating agents against colorectal cancer 4, suggesting dual roles in protective immunity and disease pathogenesis.